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Thepresenceofanonproteinogenicmoietyinanonstandardpeptideoftenimprovesthebiological propertiesofthepeptide.Non-
standard peptide libraries are therefore used to obtain valuable molecules for biological, therapeutic, and diagnostic applications.
Highly diverse non-standard peptide libraries can be generated by chemically or enzymatically modifying standard peptide
libraries synthesized by the ribosomal machinery, using posttranslational modiﬁcations. Alternatively, strategies for encoding
non-proteinogenic amino acids into the genetic code have been developed for the direct ribosomal synthesis of non-standard
peptide libraries. In the strategies for genetic code expansion, non-proteinogenic amino acids are assigned to the nonsense
codons or 4-base codons in order to add these amino acids to the universal genetic code. In contrast, in the strategies for genetic
code reprogramming, some proteinogenic amino acids are erased from the genetic code and non-proteinogenic amino acids are
reassigned to the blank codons. Here, we discuss the generation of genetically encoded non-standard peptide libraries using these
strategies and also review recent applications of these libraries to the selection of functional non-standard peptides.
1.Introduction
Nonstandard peptides, also known as unnatural peptides or
peptidomimetics, are peptide-based small molecules con-
taining a moiety that does not exist in standard (i.e., natural)
peptides composed of only 20 proteinogenic amino acids.
The nonproteinogenic moiety in nonstandard peptides, such
as a nonproteinogenic side chain, a modiﬁed backbone, or
a macrocyclized backbone, often contributes to improving
the peptide’s cell permeability, stability against peptidases,
and conformational rigidity, thereby aﬀording speciﬁc high
aﬃnity toward its target molecule [1–5]. Naturally occurring
nonribosomal peptides (e.g., immunosuppressant cyclo-
sporine A) are representative of nonstandard peptides, and
given the success of nonribosomal peptides as therapeutics,
the development of methods to construct highly diverse
drug-like nonstandard peptide libraries is important for the
discovery of novel drug candidates. Chemical synthesis can
generate highly modiﬁed drug-like nonstandard peptide
libraries,butthesizeoftheselibrariesisrelativelysmall(with
ad i v e r s i t yo fu pt o1 0 6 unique compounds). In contrast,
by using genotype-phenotype linking technology, ribosomal
synthesis can generate genetically encoded peptide libraries
with extremely high diversity (up to 1013 compounds) [6–
9]. However, ribosomally synthesized peptide libraries are
typically composed of just the 20 proteinogenic amino
acids. This had led to the development of various strategies
to generate highly diverse nonstandard peptide libraries;
thesestrategiesintegratebiology-basedmethodstoconstruct
highly diverse libraries and chemistry-based methods to
construct highly modiﬁed drug-like libraries.
One approach to generate genetically encoded nonstand-
ard peptide libraries involves the posttranslational modiﬁ-
cation of ribosomally synthesized peptide libraries. Exam-
ples include using chemical or enzymatic reactions for
the posttranslational macrocyclization of standard peptide
libraries. In the chemical cyclization approach, Heinis and
coworkers used 1, 3, 5-tris(bromomethyl)benzene to react
with three cysteine residues in peptide libraries displayed
on phages, and the resulting bicyclic peptide libraries were
used to obtain bicyclic peptide inhibitors against several
enzymes [10–12]. In the enzymatic cyclization approach,
Bosmaetal.reportedthebacterialdisplayofpeptidelibraries
cyclized with a thioether-bridge that was posttranslationally
added using enzymes, and demonstrated thioether-bridged
peptide selection against a model protein (streptavidin) [13].2 Journal of Nucleic Acids
Another example of the posttranslational conversion of stan-
dard peptide libraries to nonstandard ones is the modiﬁca-
tion of peptides with a moiety that selectively interacts with a
target protein. Li and Roberts chemically modiﬁed a peptide
library by reacting the sulfhydryl group of cysteine residues
in the library with a bromoacetamide derivative of penicillin,
and the penicillin-modiﬁed peptide library was subjected to
mRNA display selection against penicillin binding protein 2a
[14]. An excellent review discussing these posttranslational
strategies has recently been published elsewhere [15].
Another approach to generate genetically encoded non-
standard peptide libraries involves the engineering of a
ribosomal translation system, that is, cotranslational incor-
poration of nonproteinogenic amino acids into ribosomally
synthesizedpolypeptides (Figure 1).Thisapproachisfurther
divided into two strategies: genetic code expansion and
genetic code reprogramming. In this paper, we discuss
both strategies and their application for the generation of
genetically encoded nonstandard peptide libraries as well
as the use of these libraries for the selection/evolution of
functional nonstandard peptides.
2. GeneticCode Expansion
The genetic code expansion strategy (Figure 1(a))h a sb e e n
used mainly for the study of proteins rather than short
peptides because it allows the site-speciﬁc incorporation of a
21st amino acid in addition to the 20 proteinogenic amino
acids. In 1989, the amber suppression method, the ﬁrst
example of a genetic code expansion strategy, was indepen-
dently reported by Schultz’s group and Chamberlin’s group
(Figure 1(a))[ 16, 17]. In these reports, amber suppressor
tRNA(CUA) carrying a nonproteinogenic amino acid was
synthesized by chemoenzymatic acylation, which was devel-
oped by Hecht’s group [18], and the resulting aminoacyl-
tRNA (aa-tRNA) was added to an in vitro translation
system (conventional crude lysate system). Accordingly, a
polypeptide containing the nonproteinogenic amino acid
was synthesized from an mRNA bearing a site-speciﬁcally
mutated amber UAG codon to incorporate the nonpro-
teinogenic amino acid. Later, Chamberlin and coworkers
also reported that the other nonsense codons (opal UGA
codonandochreUAAcodon)couldbesuppressedeﬀectively
by the corresponding nonproteinogenic aa-tRNA in rabbit
reticulocyte lysate [19]. The extension of this nonsense
suppression method to use a four-base codon was reported
by Sisido’s group. In this approach, a nonproteinogenic aa-
tRNA bearing an ACCU four-base anticodon was used to
incorporate a nonproteinogenic amino acid at an AGGU
four-base codon [20]. They also expanded this approach
to other four-base [21–23] and even ﬁve-base codons [24]
and showed the simultaneous incorporation of multiple
nonproteinogenic amino acids into proteins [25–28]. Later,
the genetic code expansion strategy was further extended
from in vitro to in vivo. In 1995, Dougherty, Lester, and
coworkers reported in vivo nonsense suppression, where
UAG-containing mRNA and suppressor tRNA, which was
chemically acylated with a nonproteinogenic amino acid,
were injected into a Xenopus oocyte to incorporate the non-
proteinogenic amino acid into an ion channel expressed
on the surface of the oocyte [29, 30]. Further progress
came with the development of orthogonal tRNA(CUA) and
aminoacyl-tRNA synthetase (aaRS) pairs, which produce an
orthogonal tRNA(CUA) carrying a nonproteinogenic amino
acid in vivo under multiple turnover conditions. This
technologyallowsustonotonlysynthesizeaproteincarrying
a nonproteinogenic amino acid at a speciﬁc position in
various types of cells, but also obtain a protein containing
a nonproteinogenic amino acid in a larger quantity than by
in vitro genetic code expansion [31–34]. The use of various
orthogonal tRNA/aaRS pairs has allowed for the synthesis of
proteins carrying various artiﬁcial functional groups, such
a sab i o c h e m i c a lg r o u p( e . g . ,s u l f a t e ,a c e t a t e ,o rm e t h y l a t e )
[35–38], ﬂuorescent probe [39–43], photo-cross-linker [44–
49], photo-caged group [50–56], and bioorthogonal reactive
group [57–63], for the study of protein structure and
function. Similarly to in vitro genetic code expansion, in
vivo amber suppression using orthogonal tRNA/aaRS pairs
was extended to ochre and opal codon suppression [64–
66] and four-base codon suppression to incorporate two
nonproteinogenic amino acids simultaneously into proteins
in vivo [67, 68].
3.Selection of FunctionalNonstandard
PeptidesGeneratedby Genetic
Code Expansion
The in vivo genetic code expansion strategy has recently
been used to generate nonstandard peptide libraries. Using
orthogonal aaRS/tRNA(CUA) pairs, Young et al. generated
a backbone-cyclized peptide library containing a nonpro-
teinogenic amino acid and performed in-cell selection of
a nonstandard peptide inhibitor from the library (Figure
2(a))[ 69]. The orthogonal aaRS/tRNA(CUA) pairs were
expressed in Escherichia coli (E. coli) in order to assign L-p-
benzoylphenylalaninetotheambercodon[46].Additionally,
the split intein catalyzed ligation of proteins and peptides
(SICROPPS) method, which was developed by Benkovic’s
group [70, 71], was used to cyclize the backbone of a
ribosomally synthesized peptide library containing L-p-
benzoylphenylalanine. The activity-based in-cell selection of
human immunodeﬁciency virus (HIV) protease inhibitors
from the cyclic peptide library was performed by linking the
protease inhibitory activity of a cyclic peptide to cell viability
of the host E. coli. The most abundant peptide obtained after
two rounds of selection inhibited HIV protease activity at a
low micromolar concentration (IC50 = 0.96μM). Interest-
ingly, the L-p-benzoylphenylalanine residue of the peptide
formedacovalentSchiﬀ-baseadductwiththeε-aminogroup
of Lys14 of the HIV protease.
Although this study using in vivo selection succeeded
in selecting new functional nonstandard peptides, the size
of the library was limited by the transformation eﬃciency
of E. coli. In contrast, in vitro display methods, such as
ribosome display [7] and mRNA display (or in vitro virus)Journal of Nucleic Acids 3
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Figure 1: Generation of genetically encoded libraries of nonstandard peptides. (a) Genetic code expansion. Nonproteinogenic amino acids
are assigned to the amber codon and four-base codons. (b) Reprogramming the genetic code. Nonproteinogenic amino acids are reassigned
to blank codons generated by reconstructing a cell-free translation system with a reduced number of amino acids and protein factors. nZ
(n = 1–9) represents one of the nonproteinogenic amino acids.
[8, 9], can generate highly diverse libraries (up to 1013 com-
pounds) because library construction does not involve cell
transformation. Moreover, in vitro genetic code expansion
has an advantage over in vivo expansion because membrane-
impermeable, metabolically unstable or cytotoxic nonpro-
teinogenic amino acids can be used as the building blocks for
genetically encoded nonstandard peptides. The ﬁrst proof of
concept study of an in vitro display selection from a library
containing a nonproteinogenic amino acid was reported
by Li et al. (Figure 2(b))[ 72, 73]. A nonstandard peptide
library displayed on mRNA was prepared by using a lysate
translationsystemcontainingambersuppressortRNA(CUA)
precharged with biocytin and a puromycin-modiﬁed mRNA
library containing one NNS (S = C or G) codon. The authors
demonstrated that mRNA containing the UAG codon (i.e.,
encoding a biocytin-containing peptide) was selectively
recoveredfromthepreparedlibrarybypulldownusingstrep-
tavidin beads. The same group combined a similar genetic
code expansion strategy with a posttranslational chemical
cyclization method to generate a nonstandard cyclic peptide
library [74]. A peptide library containing N-methyl-L-
phenylalanine assigned to the amber codon was displayed on
mRNA and chemically converted to a cyclic peptide library
by linking the N-terminal α-amino group to the ε-amino
group of a lysine residue using disuccinimidyl glutarate. This
library was used to select Gαi1 binding peptides, and the
best binding cyclic peptide had very high aﬃnity against
Gαi1 (2.1nM). Although this cyclic peptide also showed
higher proteolytic stability than its linear counterpart, the
in vitro-selected peptides in this study unfortunately did not
contain the nonproteinogenic amino acid. Muranaka et al.
also reported the selection of a streptavidin-binding peptide
from nonstandard peptide libraries prepared by combining
the amber and four-base codon suppression approaches
(Figure 2(c))[ 75]. Messenger RNA libraries composed of
nine NNK (K = U or G) codons and one VGGU (V = C,
A, or G) four-base codon were used to construct non-
standard peptide libraries in the mRNA display format,
and a streptavidin-binding non-standard peptide was suc-
cessfully selected. The selected peptide contained only one
nonproteinogenic amino acid (L-p-benzoylphenylalanine)
residue (Figure 2(c)), even though multiple nonproteino-
genic amino acids could have appeared in the sequence of
the used libraries.
4. Limitation of GeneticCode
Expansion for the Preparation of
Nonstandard PeptideLibraries
In principle, highly modiﬁed non-standard peptides con-
taining multiple nonproteinogenic amino acids can be
produced by genetic code expansion, but this strategy
actually imposes considerable restrictions on the synthesis
of such peptides. In this strategy, the incorporation of
nonproteinogenic amino acids competes with other normal
events during translation. For example, an amber suppressor
nonproteinogenic aa-tRNA(CUA) competes with endoge-
nous release factor 1 (RF-1), which results in the production
of truncated as well as full-length peptides from one mRNA
template [16, 17]. Similarly, a 4-base suppressor non-
proteinogenic aa-tRNA(ACCU) competes with endogenous
Arg-tRNAArg(CCU) for decoding the AGG(U) codon, which
resultsintheproductionofamixtureofin-frameandout-of-
f r a m ep r o d u c t sf r o mo n em R N At e m p l a t e[ 20]. This feature
makes it diﬃcult to simultaneously incorporate multiple
nonproteinogenic amino acids into a peptide since the yield
of a full-length (in-frame) peptide decreases exponentially
as the number of nonproteinogenic amino acids increases.
Moreover, in these genetic code expansion strategies, an
mRNA containing the nonsense or 4-base codon does not
encode one peptide but a mixture of multiple peptide4 Journal of Nucleic Acids
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Figure 2: Selection of nonstandard peptides from libraries generated by genetic code expansion. (a) Selection of backbone-cyclized L-p-
benzoylphenylalanine-containing peptide inhibitors. Orthogonal tRNA(CUA)/aaRS pairs were expressed in E. coli in order to assign L-p-
benzoylphenylalanine to the amber codon. SICROPPS was used to cyclize the peptides. (b) Proof-of-concept study of mRNA display with
a nonproteinogenic amino acid. Biocytin was assigned to the amber codon by adding biocytin-tRNA(CUA) to a rabbit reticulocyte lysate.
The peptides were expressed in mRNA display format and pulled down using streptavidin beads. (c) Selection of streptavidin binding non-
standard peptides. Four nonproteinogenic amino acids were assigned to the amber codon and four-base codons (UAG, L-2-naphthylalanine;
AGGU,L-p-biphenylalanine;CGGU,L-p-benzoylphenylalanine;GGGU,L-p-phenylazophenylalanine).Allcorrespondingnonproteinogenic
aa-tRNAs were added to an E. coli cell-free translation system. The peptide libraries were expressed in mRNA display format and used for
in vitro selection against streptavidin. X represents one of the proteinogenic or nonproteinogenic amino acids, and Z represents one of the
nonproteinogenic amino acids.
products. This could be a more critical problem for peptide
selection because this phenomenon would make it diﬃcult
to identify an active species from selected cDNA sequences.
Recently, as one of the approaches used to decrease these
competing translation events, Chin and coworkers evolved
an orthogonal mutant ribosome that is thought to have
a decreased functional interaction with RF-1 and demon-
strated the increased incorporation eﬃciency of a nonpro-
teinogenic amino acid on the amber codon [76]. However,
sincetheorthogonalmutantribosomewasstillrecognizedby
RF-1 to some extent, a mixture of full-length and truncated
proteins was expressed from one UAG-containing mRNA.
Similarly, Liu and coworkers prepared a ribosome with the
C-terminal domain of ribosomal protein L11 to decrease RF-
1-mediated translation termination; however, the complete
reassignment of the amber codon was not shown [77].
Conversely, Sakamoto’s group [78–80] and Wang’s group
[81, 82] independently reported using a diﬀerent approach
to knock out RF-1 from E. coli strains, and both groups
demonstrated complete reassignment of the amber UAG
codon from translation termination to nonproteinogenic
amino acid incorporation in vivo. In Wang’s approach,
the RF-1 knockout strains had a substantially decreased
growth rate, most likely because of the failure of translation
termination at amber UAG codons in endogenous mRNAs
that are essential for the growth of E. coli. The combinationJournal of Nucleic Acids 5
of this RF-1 knockout approach with the recently reported
genome-wide codon replacement method to replace all 314
endogenous UAG codons to UAA stop codons in E. coli [83]
might solve this problem. Nevertheless, these RF-1 knockout
strategies enabled the complete reassignment of the amber
codon to a nonproteinogenic amino acid in vivo;h o w e v e r ,
they have only been applied to the amber codon thus far.
The diﬃculty of complete codon reassignment in vivo
clearly comes from the fact that the translation events that
compete with the incorporation of nonproteinogenic amino
acids are required to maintain the life of the host cells.
Conversely, engineering an in vitro translation system is not
as complicated as for an in vivo translation system; even so,
the simultaneous complete reassignment of multiple codons
to diﬀerent nonproteinogenic amino acids was not achieved
until 2003. For example, Roberts and coworkers used a lysate
translation system pretreated with aminoethanol-Sepharose
to remove endogenous tRNAs, which compete with the
incorporation of a nonproteinogenic amino acid at sense
codons. However, a peptide synthesized by using this tRNA-
depleted system still consisted of a mixture of proteinogenic
and nonproteinogenic amino acids [2]. Other approaches
to decrease competitive translation events against nonpro-
teinogenic amino acid incorporation in vitro include heat
inactivation of RF-1 [84], aptamer-mediated RF-1 inhibition
[85], and antibody-mediated RF-1 inhibition [86], yet none
of these resulted in complete codon reassignment. Another
interesting approach is the pretreatment of a lysate transla-
tion system with a phenylalanyl-tRNA synthetase (PheRS)
inhibitor, and nearly complete reassignment of the Phe sense
codon to naphthylalanine was demonstrated, although its
general application to multiple codons has yet to be reported
[87].
5.GeneticCode Reprogramming
The ﬁrst demonstration of the simultaneous complete reas-
signment of multiple codons to diﬀerent nonproteinogenic
aminoacids(i.e.,geneticcodereprogramming)wasreported
by Forster et al. in 2003 (Figure 3(a))[ 88]. The key feature
of genetic code reprogramming is the use of a reconsti-
tuted translation system, instead of crude lysate translation
system, to eliminate translation events that compete with
the incorporation of no-proteinogenic amino acids. In the
report by Forster et al., puriﬁed ribosomes, initiation factors,
and elongation factors were mixed with fMet-tRNAini,G l u -
tRNAGlu,andthreekindsofchemoenzymaticallysynthesized
nonproteinogenic aa-tRNA which were assigned in the
reprogrammed genetic code shown in Figure 3(a),a n da
non-standard peptide containing three diﬀerent nonpro-
teinogenic amino acids was synthesized. An interesting fea-
tureoftheiraaRS-freereconstitutedtranslationsystemisthat
since orthogonality of the tRNA against aaRS is not required,
in principle, tRNA with any body sequence and anticodon
can be used to incorporate amino acids [89]. On the other
hand, in their genetic code reprogramming system using
chemoenzymatic tRNA-acylation, the maximum number
of nonproteinogenic amino acids that were simultaneously
reassigned in the reprogrammed genetic code was not more
than three [88, 90–92], probably because the authors used a
technicallydemandingchemoenzymaticacylationmethodto
prepare the aa-tRNAs [18].
Toachievegeneticcodereprogrammingbyamoresimple
tRNA-acylation method, Szostak’s group took advantage of
the substrate tolerance of wild-type aaRSs, namely, that
“wild-type” aaRSs can charge some proteinogenic amino
acid analogs [93]. This feature has been used mainly to
incorporate a proteinogenic amino acid analog into proteins
in vivo (in an auxotrophic strain in many cases) in a
residue-speciﬁc manner to produce heterogeneous proteins
containing proteinogenic and nonproteinogenic amino acids
as engineered protein material [94–97]. In the ﬁrst report
of genetic code reprogramming by aaRS-catalyzed acylation,
Josephson et al. described a landmark example [93]i n
which nonproteinogenic amino acids were misacylated onto
endogenous tRNAs by wild-type aaRSs in a reconstituted
translation system [98] lacking the corresponding proteino-
genic amino acids, and 10 diﬀerent nonproteinogenic amino
acids were incorporated simultaneously into a peptide as
assigned in the reprogrammed genetic code (Figure 3(b)).
Importantly, they also demonstrated that the same non-
standard peptide could be displayed on its encoding mRNA
via a puromycin linker to show the compatibility of genetic
code reprogramming with mRNA display. Later, Szostak’s
group found that over 90 nonproteinogenic amino acids
couldbechargedontotRNAsbywild-typeandmutantaaRSs
and showed that over 50 nonproteinogenic amino acids
could be ribosomally incorporated into peptides [99, 100].
They also synthesized a non-standard peptide containing
13 diﬀerent nonproteinogenic amino acids. In terms of the
number of diﬀerent nonproteinogenic amino acids that can
beincorporatedsimultaneouslyintoribosomalpeptides,this
non-standardpeptidestillholdstherecord.Theadvantageof
Szostak’s reprogramming method is that (1) the misacylated
tRNAs can be generated in situ under multiple turnover
conditions and (2) non-standard peptides can be expressed
bymerelyaddingnonproteinogenicaminoacidstothetrans-
lation system from which the corresponding proteinogenic
amino acids are withdrawn. On the other hand, the number
of available nonproteinogenic amino acids is limited since
aaRSscangenerallymischargeonlythosethatarestructurally
similar to proteinogenic amino acids, and it is not possible
to introduce multiple analogs of the same amino acid type
at the same time (e.g., two proline analogs). Moreover,
since proteinogenic amino acids are more acceptable to
both aaRS acylation and ribosomal translation, even a tiny
amount of proteinogenic amino acid contamination causes
the production of undesired product that consists of a
mixture of proteinogenic and nonproteinogenic amino acids
[93].
As another approach to achieve genetic code reprogram-
ming by a more general tRNA-acylation method, Murakami
et al. reported a highly ﬂexible-ribozyme- (ﬂexizyme-) based
tRNA-acylation system [101]. In the ﬁrst demonstration
of genetic code reprogramming using ﬂexizymes, three
sense codons were reassigned to three nonproteinogenic
amino acids charged onto orthogonal tRNAs (Figure 3(c)).6 Journal of Nucleic Acids
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Figure 3: Comparison of the aminoacylation methods used for genetic code reprogramming. (a) Chemoenzymatic acylation method. The
dinucleotide carrying the nonproteinogenic amino acid (pdCpA-aa) was enzymatically ligated to tRNA lacking 3 -nucleotides (pCpA).
Aminoacyl-tRNAs prepared by the chemoenzymatic acylation method were added to an aaRS-free reconstituted translation system to
synthesize a non-standard peptide containing three nonproteinogenic residues (1Z, L-propargylglycine; 2Z, L-O-methylserine; 3Z, L-
allylglycine). (b) aaRS tRNA-misacylation method. Aminoacyl-tRNAs carrying nonproteinogenic amino acids were enzymatically generated
in a reconstituted translation system. A non-standard peptide containing 13 nonproteinogenic residues was synthesized (NX, an analog
of proteinogenic amino acid X). (c) Flexizyme-based acylation method. An activated amino acid was mixed with tRNAs and ﬂexizyme to
synthesize aminoacyl-tRNA. Aminoacyl-tRNAs prepared by the ﬂexizyme-based method were added to a reconstituted translation system to
synthesizeanon-standardpeptidecontainingsixnonproteinogenicresidues(4Z,L-acetyllysine; 5Z,L-citrulline; 6Z,L-p-iodophenylalanine).
According to the reprogrammed genetic code, a 17 mer non-
standard peptide possessing six nonproteinogenic amino
acids was synthesized in a genetically encoded manner.
Theprototype[102]oftheﬂexizymeusedingeneticcode
reprogramming, which was evolved from a random RNA
pool, has expanded its acceptability of tRNAs [103, 104]
and amino acids for aminoacylation and turned into highly
ﬂexible ribozymes for tRNA aminoacylation [101, 105, 106].
Because the ﬂexizymes recognize their cognate aromatic
group, they are able to charge a wide variety of not only L-
aminoacidswithnonproteinogenicsidechains[3,107–111],
but also amino acids with an altered backbone such as N-
alkyl amino acids [112–114], N-acyl amino acids [115], D-
amino acids [116], β-amino acids, oligopeptides [117, 118],
and even hydroxy acids [119, 120]. Moreover, as the prepara-
tionofaa-tRNAsbyﬂexizymesissimpleandstraightforward,
it should facilitate the parallel preparation of various aa-
tRNAs in a high-throughput manner, which enables us to
carry out genetic code reprogramming conveniently. In fact,
more than 160 kinds of (amino) acids were charged onto
tRNAs using the ﬂexizyme system in the past few years. Since
ﬂexizymes also recognize conserved 3 -terminal three bases
(CCA-3 )oftRNA,theycanaminoacylatevirtuallyanytRNA
[103, 104]. Recently, Cornish and coworkers took advantage
of this tRNA ﬂexibility of ﬂexizymes to aminoacylate base-
modiﬁedtRNAswiththeirnoncognateaminoacidsandused
the prepared aa-tRNAs to investigate diﬀerences in ribosome
recognition between the amino acid charged onto cognate
and noncognate tRNAs [121].
Bearing the advantages and disadvantages of each genetic
code reprogramming method in mind, scientists in this
research ﬁeld moved onto the next step to select func-
tional non-standard peptides from genetically encoded non-
standard peptide libraries.
6.Selection ofFunctional
Nonstandard Peptides Generated by
GeneticCode Reprogramming
The ﬁrst model study of the in vitro display selection of a
non-standard peptide prepared with a reconstituted transla-
tion system was reported by Forster et al. [122]. Five kinds of
biotinylatedpeptidesbearingdiﬀerentlengthsofpolypeptideJournal of Nucleic Acids 7
spacer were synthesized in a ribosome display format, and
biotinylated peptides with a spacer long enough to exit from
the ribosome tunnel were selectively pulled down using
streptavidin beads. However, in this paper, a diverse non-
standard peptide library was not constructed and a novel
functional non-standard peptide was not obtained. Very
recently, several papers have been published on the selection
of functional non-standard peptides by combining genetic
code reprogramming with mRNA display selection. In this
section, we review the preparation of non-standard libraries
and the results of the selection in these reports.
In 2011, Suga’s group published an important study
in which highly diverse non-standard peptide libraries
containing multiple diﬀerent nonproteinogenic amino acids
were constructed in an mRNA display format, and a novel
non-standard peptide was selected from the libraries [5,
123]. Previously, the same group used the ﬂexizyme system
to examine the synthesis of various non-standard peptides
in a ribosomal translation system [124] and reported the
followingﬁndings:(1)anN-chloroacetyl-aminoacidresidue
andcysteineresidueonthesamepeptidewerespontaneously
reacted in situ using a reconstituted translation system to
give a thioether-cyclized peptide without an intermolecular
side reaction between the N-terminal chloroacetyl group on
the peptide and the sulfhydryl group of the other translation
component such as a cysteine monomer and DTT [3, 108,
112, 113, 115, 125]; (2) N-methyl amino acids with an
aromatic side chain or noncharged and nonbulky side chains
are eﬃciently incorporated into peptides by the ribosome,
and multiple N-methyl amino acids can be incorporated
simultaneously into a peptide to give various sequences
of thioether-cyclized N-methyl-peptides [112]; and (3) the
translation initiation apparatus accepts D-amino acids with
hydrophobic side chain as relatively good initiators, and
pre-N-acylation of D-aa-tRNA dramatically increases the
eﬃciencyoftranslationinitiation[116].Onthebasisofthese
studies, Yamagishi et al. generated non-standard peptide
libraries in which N-chloroacetyl-D-tryptophan was reas-
signed to the AUG start codon and N-methyl-phenylalanine,
N-methyl-serine, N-methyl-glycine, and N-methyl-alanine
were individually reassigned to the UUU, CUU, AUU, and
GCU codons, respectively (Figure 4(a))[ 5]. The thioether-
cyclizedN-methyl-peptidelibrariescontaining8–15random
residues were expressed in the mRNA display format by
using a translation system reconstituted from a limited set
of proteinogenic amino acids and their cognate aaRSs. After
reverse transcription, the non-standard peptide libraries
were used without any puriﬁcation for in vitro selection
against site-speciﬁcally biotinylated E6-associated protein
(E6AP) together with negative selection using E6AP-free
beads. Signiﬁcantly, unlike the previous report of in vitro
selection from cyclic peptide library containing an N-
methyl amino acid with genetic code expansion where
the selected peptides did not contain the N-methyl amino
acid [74], all of the peptides obtained after this in vitro
selection contained multiple diﬀerent N-methyl amino acids
inside the macrocyclized peptide ring. The most abundant
cyclic N-methyl-peptide among the sequenced clones was
chemically synthesized and further characterized. The cyclic
N-methyl-peptide exhibited high aﬃnity for E6AP (0.6nM),
and despite the fact that the peptide sequence was obtained
by aﬃnity selection, it inhibited self-ubiquitination of E6AP
in vitro. More importantly, removing all of the N-methyl
groups from the backbone of the cyclic N-methyl-peptide
dramatically decreased its aﬃnity for E6AP, suggesting that
suchacyclicN-methyl-peptideisnearlyimpossibletoobtain
using conventional approaches, such as the combination
of selection from standard peptide libraries and following
N-methyl modiﬁcation of the selected peptide. Also, the
cyclic N-methyl peptide showed 200-times higher aﬃnity
than its linear counterpart, which demonstrates that macro-
cyclization of the N-methyl-peptide is important for its
binding to E6AP. Moreover, it was shown that both the N-
methylated backbone and macrocyclization of the cyclic N-
methyl peptide also contributed to the stability of the cyclic
N-methyl-peptide against peptidases in human plasma.
The same research group also obtained protein kinase
Akt2 inhibitors by mRNA display selection from thioether-
cyclized peptide libraries generated by using the ﬂexizyme
system (Figure 4(b))[ 126]. Peptide libraries containing 4–
12 random residues cyclized with either L or D isomers
of N-chloroacetyl-tyrosine reassigned to the initiation AUG
codon were expressed and used for selection against Akt2
immobilized on Ni-NTA beads together with negative
selection against Akt2-free beads to remove His-tagged
translation components and undesired bead binders. After
six rounds of selection, the selected cyclic L- and D-peptides
converged to completely distinct sequences, indicating that
one conﬁgurational diﬀerence in the macrocyclized peptides
may provide diﬀerent sequence spaces. In this study, even
though enzymatically inactive Akt2 was used for selection,
some of the selected peptides showed potent inhibitory
activity against active Akt2. On the other hand, despite the
fact that the recovery rate after the six rounds of selection
between the enriched L- and D-peptide display libraries was
at the same level, the most abundant L- and D-peptides
showed a diﬀerent level of inhibitory activity. In addition,
the frequency of the selected peptides did not correlate with
the inhibitory potency of the selected peptides, indicating
the diﬃculty in identifying the best inhibitor by using only
binding-based selection. Even so, the authors successfully
obtained potent Akt2 inhibitors by screening chemically
synthesizedmultiplepeptidesdiscoveredbyinvitroselection.
Interestingly, in vitro inhibition assays of the selected L-
peptides revealed not only high kinase family speciﬁcity but
also high Akt isoform speciﬁcity, for example, Akt2 (IC50 =
110nM) over Akt1 (IC50 ≥ 25,000nM) and Akt3 (IC50 =
4,200nM) for Pakti-L1 peptide.
To obtain strong inhibitors by using binding-based
in vitro selection, Morimoto et al. performed mRNA
display selection from cyclic peptide libraries contain-
ing N-6-triﬂuoroacetyl-L-lysine (CF3K), a nonproteinogenic
amino acid inhibitor of its target enzyme (Figure 4(c))
[127]. In this paper, in addition to each enantiomer of
N-chloroacetyl-tyrosine at the initiation AUG codon, CF3K
wassimultaneouslyreassignedtotheelongationAUGcodon.
Thioether-cyclized CF3K-peptide libraries containing 7–11
random residues were prepared and used to select against8 Journal of Nucleic Acids
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Figure 4:Selectionofnonstandardpeptidesfromlibrariesgeneratedbyﬂexizyme-basedgeneticcodereprogramming.Theﬂexizymesystem
was used to acylate tRNAs with nonproteinogenic amino acids. The nonstandard peptide libraries were expressed in a reconstituted cell-free
translation system in the mRNA display format. (a)Selection of cyclic N-methyl-peptides against E6AP. N-Chloroacetyl-D-tryptophan was
reassigned to AUG, and four N-methyl-L-amino acids were independently reassigned to one of the NNU codons. (b)Selection of thioether-
cyclized peptides against Akt2. Each enantiomer of N-chloroacetyltyrosine was reassigned to the initiation AUG codon. (c)Selection of cyclic
peptides containing N-6-triﬂuoroacetyl-L lysine against sirtuin 2 (SIRT2). Each enantiomer of N-chloroacetyl-tyrosine was reassigned to
the initiation AUG codon and N-6-triﬂuoroacetyl-L-lysine (CF3K) was reassigned to the elongation AUG codon.Journal of Nucleic Acids 9
NAD-dependent deacetylase sirtuin-2 (SIRT2) immobilized
on Ni-NTA beads. After six or seven rounds of selection,
although various sequences were seen at the randomized
positions, the R-I/V-CF3K-RY sequence was preferred in the
vicinity of the N-6-triﬂuoroacetyl-L-lysine residue. After
conﬁrming the inhibition of in vitro-selected cyclic CF3K-
peptides expressed in the translation system, in vitro binding
and inhibition assays were performed against two chemically
synthesized representative cyclic CF3K-peptides. Importantly,
the inhibitory activity of the cyclic CF3K-peptides against
SIRT2 correlated well with their binding activity toward
SIRT2, and the peptides exhibited high inhibitory activity
against SIRT2 (IC50 = 3-4nM). On the other hand, the
cyclic CF3K-peptides showed a similar IC50 value against
SIRT2 to their linear versions (5-6nM), and the authors
showed that the R-I/V-CF3K-RY short peptide segment con-
tributed strongly to their SIRT2 inhibitory activity, whereas
the constrained macrocyclic structure did not make much
contribution. Similarly to the in vitro-selected Akt2 inhibitor
peptides, in vitro-selected SIRT2 inhibitor peptides also
showed isoform speciﬁcity against SIRT2 (IC50 = 3.2nM)
over SIRT1 (IC50 = 47nM) and SIRT3 (IC50 = 480nM).
By taking a diﬀerent genetic code reprogramming
method from Suga’s group, Szostak’s group demonstrated
mRNA display selection from a highly modiﬁed non-
standard peptide library containing 12 diﬀerent proteino-
genic amino acid analogs (Figure 5(a))[ 128]. A peptide
library containing 10 random residues between 2Cys
residues was expressed and displayed on encoding mRNAs in
the reconstituted translation system with 8 proteinogenic
amino acids and 12 nonproteinogenic amino acids. The
peptide-mRNA fusion libraries were then cyclized by the
addition of 1,3-di(bromomethyl)benzene after oligo-dT
puriﬁcation. After reverse transcription and Ni-NTA puriﬁ-
cation, the non-standard cyclic peptide library was subjected
to selection against biotinylated thrombin protease, and
active species were eluted selectively from streptavidin beads
using the thrombin inhibitor hirudin. After 10 rounds of
selection, several conserved sequences were observed, and
importantly, the selected peptides had 50% nonproteino-
genic amino acids in sequences that were distinct from the
sequences obtained by selection using proteinogenic amino
acids. The two most abundant peptides synthesized by the
ribosomal translation system showed high aﬃnity (Kd = 4.5
and 20nM) and inhibitory activity (K
app
i = 23 and 35nM)
against thrombin, while the parent linear peptides did not.
Moreover, the “proteinogenic analogs” of the two peptides
did not bind to thrombin (Kd > 500nM), suggesting that
the incorporation of side-chain-modiﬁed amino acids may
provide a diﬀerent sequence space from that obtained with
proteinogenic amino acids.
By using a similar approach, Hofmann et al. reported
mRNA display selection from lanthionine-containing cyclic
peptide libraries generated by the ribosomal incorporation
of L-4-selenalysine (Figure 5(b))[ 129]. 4-Selenalysine was
reassigned to the AAA codon by adding 4-selenalysine
instead of lysine to a reconstituted translation system, and a
librarycontainingninerandomresidueswasgenerated.After
oligo-dTpuriﬁcation,the4-selenalysineresiduewasoxidized
and converted to dehydroalanine, which was then reacted
with the sulfhydryl group on the cysteine residue [130, 131].
After reverse transcription and Ni-NTA puriﬁcation, the
resulting cyclic lantipeptide libraries were used for selection
against chemically biotinylated sortase A. After ﬁve rounds
of selection, several conserved sequences were obtained,
and the stereochemistry of the selected lantipeptides was
determined through chemical peptide synthesis. While the
peptides from one family bound sortase A with an aﬃnity
of 3–32μM, none of the peptides from the other family
bound it, suggesting that the sequences in the second family
were selected by a diﬀerent selection pressure from sortase
A binding. Moreover, the best sortase A binding peptide did
not inhibit its activity.
Taken together, genetic code reprogramming has been
successfully combined with in vitro display for the selection
of non-standard peptide libraries, and it has been shown
that most non-standard peptides obtained by this method
possess inhibitory activity in vitro.F u t u r ew o r kw i l li n v o l v e
demonstrating the activity of the obtained non-standard
peptides in vivo (not only in cultured cells, but also in an
animal model).
7. Conclusions and Perspectives
In this paper, we have described the current strategies
for the generation of genetically encoded libraries of non-
standard peptides and the application of these strategies to
the selection of novel functional non-standard peptides. The
potential of non-standard peptides has markedly increased
following the development of technologies that can generate
highly diverse libraries of drug-like non-standard peptides.
However, although the selection of several non-standard
peptides has been demonstrated, some problems remain to
be addressed. One is that there are some limitations to the
types of nonproteinogenic amino acids that can be used
in a ribosomal translation system. Although the translation
system accepts a variety of side-chain-modiﬁed amino
acids [22, 132], backbone-modiﬁed amino acids are less
compatible with a ribosomal translation system. For exam-
ple, Tan et al. showed that D-amino acids (D-alanine, D-
phenylalanine) and β-amino acids (homo-L-alanine, homo-
L-phenylalanine) were not compatible with their reconsti-
tuted translation system [133], and Hartman et al. also
showed that several β-amino acids were not compatible with
their reconstituted translation system [100]. We believe that
more precise experiments will be required to determine
the compatibility of D- and β-amino acids with ribosomal
translation systems. Following this reevaluation of nonpro-
teinogenic amino acids, further studies on the engineering
of translation factors, such as the ribosome [134–136],
elongation factorTu[137,138],andtRNA[139–141],willbe
required to overcome these limitations. The second problem
is the low cell permeability of peptides. Many potential drug
targets are located inside cells, requiring that non-standard
peptideshavegoodcellpermeability.SincetheN-alkylgroup
increases the permeability of a peptide, the incorporation
of N-alkyl-amino acids into the genetic code might address10 Journal of Nucleic Acids
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Figure 5: Selection of nonstandard peptides from libraries generated by aaRS-based genetic code reprogramming. Nonproteinogenic
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this problem [112, 113, 142, 143]. Another problem is
the fact that the mRNA display method used for selection
from highly diverse non-standard peptide libraries is still a
laborious and time-consuming technique involving multiple
steps. A method to prepare peptide/DNA or peptide/mRNA
complexlibrariescontinuouslyfromthecorrespondingDNA
libraries such as CIS display or ribosome display may
allow for high-speed library preparation, even though these
methods have not been applied to the generation of a highly
diverse non-standard peptide library [7, 144]. Nevertheless,
it is clear that more improvements of in vitro display
techniques are required for the development of high-speed
non-standard peptide selection.
Genetic code expansion and reprogramming strategies
enable us to generate genetically encoded libraries of non-
standard peptides. The value of non-standard peptide
libraries will increase as these strategies are developed
further.Selectionfromthegeneticallyencodednon-standard
peptide libraries will provide new ways to generate various
novel functional peptides that are valuable for biological,
therapeutic, and diagnostic applications.
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